期刊文献+

二苯乙烯苷对脂肪肝家鸭模型肝脂的干预效果及机制研究 被引量:1

Mechanism and Interventional Effect of Stilbene Glycoside on Liver Lipid in Model Ducks with Fatty Liver
下载PDF
导出
摘要 目的:考查二苯乙烯苷对脂肪肝家鸭模型肝脂的干预效果,探讨其作用机制。方法:复制脂肪肝家鸭模型,以二苯乙烯苷进行干预,考查家鸭体重、肝指数、肝脂、脂蛋白脂肪酶(LPL)、肝脂酶(HL)、肝脏病理变化,并进行统计分析。结果:二苯乙烯苷具有降低脂肪肝家鸭模型体重、肝指数、肝脏TG、TC,升高肝脏LPL、HL活性,改善肝脏病理形态的作用。不同剂量二苯乙烯苷干预脂肪肝效果有所差异,在剂量为13~52mg范围内随剂量递增,效果渐佳。结论:二苯乙烯苷具有抗脂肪肝作用,且呈剂量依赖性,其机制可能与提高肝脏LPL、HL活性,调节脂代谢,保护肝细胞有关。 Objective:To study the interventional effects and therapeutic mechanism of stilbene glycoside on liver lipid in a duck models with fatty liver.Methods:Established the duck models of fatty liver.After treated with stilbene glycoside,the index of body weight,ratio of liver weight/body weight,liver lipid,lipoprotein lipase(LPL),hepatic lipase(HL),liver pathology,liver functional influence was observed and compared between each group.Results:Stilbene glycoside team can decreased the body weight,ratio of liver weight/body weight,liver TG and TC,improved the LPL and HL activities,and meliorated liver pathological changes of model ducks.Stilbene glycoside team of different doses had different interventional effects in the experiment.The increase of doses accompanied by gradually adding effect in the 13~52mg doses.Conclusion:Stilbene glycoside can improve the fatty liver excellently in a dose-dependent manner.Therapeutic mechanism of its may be related to improving the LPL and HL activities,adjusting the disorder of lipid metabolism,protecting liver cell.
机构地区 天津中医药大学
出处 《辽宁中医杂志》 CAS 北大核心 2010年第1期172-174,共3页 Liaoning Journal of Traditional Chinese Medicine
基金 国家自然科学基金(30472210)
关键词 脂肪肝 动物模型 家鸭 肝脂 二苯乙烯苷 fatty liver fatty liver model duck liver lipid stilbene glycoside
  • 相关文献

参考文献4

二级参考文献34

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2范建高 曾民德 等.上海市4009名机关职员脂肪肝流行病学调查[J].中华肝脏病杂志,1998,6(1):17-17.
  • 3Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: Implications for epidemiologic studies. Gastroenterology, 2003, 124:248-250.
  • 4Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease.Gastroenterology, 2002, 123: 1705-1725.
  • 5Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology, 2004, 39: 476-483.
  • 6Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med,2000, 132: 112-117.
  • 7Omagari K, Kadokawa Y, Masuda J, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol, 2002, 17:1098-1105.
  • 8Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 9Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 10Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.

共引文献2145

同被引文献12

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部